"description","rationale","instanceType","uuid:ID","name","id","label"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","f568a579-5d84-4d99-87b4-9a27d95866ba","Study Design 1","StudyDesign_1",""
